Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 2.96% is 12% below its 5-year average of 3.36%, around the middle of its 5-year range (0.96%–5.43%).
As of the fiscal period ended Tuesday, June 30, 2026. 28.39% below its 12-month average of 4.13%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
2.96%
RETURN ON EQUITY (ROE) AVG TTM
4.13%
RETURN ON EQUITY (ROE) AVG 3Y
4.23%
RETURN ON EQUITY (ROE) AVG 5Y
3.36%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-28.39%
CURRENT VS 3Y AVG
-30.00%
CURRENT VS 5Y AVG
-12.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
11.44%
median of 88 covered companies
CURRENT VS SECTOR MEDIAN
-74.12%
vs the sector median at left
Market Cap
$34.60B
Return on Equity (ROE)
23.13%
TTM Avg
23.30%
3Y Avg
22.33%
5Y Avg
21.49%
Market Cap
$34.13B
Return on Equity (ROE)
38.14%
TTM Avg
28.93%
3Y Avg
25.01%
5Y Avg
22.95%
Market Cap
$32.38B
Return on Equity (ROE)
14.51%
TTM Avg
21.84%
3Y Avg
21.53%
5Y Avg
32.27%
Market Cap
$32.15B
Return on Equity (ROE)
83.10%
TTM Avg
66.19%
3Y Avg
56.82%
5Y Avg
52.60%
Market Cap
$32.10B
Return on Equity (ROE)
4.43%
TTM Avg
8.42%
3Y Avg
11.86%
5Y Avg
16.52%
Market Cap
$31.95B
Return on Equity (ROE)
-22.60%
TTM Avg
-10.46%
3Y Avg
-1.37%
5Y Avg
1.10%
Market Cap
$31.37B
Return on Equity (ROE)
59.67%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
Market Cap
$31.00B
Return on Equity (ROE)
1.09%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alcon Inc. (ALC) | $34.88B | 2.96% | 4.13% | 4.23% | 3.36% |
| ResMed Inc. (RMD)vs › | $34.60B | 23.13% | 23.30% | 22.33% | 21.49% |
| DexCom, Inc. (DXCM)vs › | $34.13B | 38.14% | 28.93% | 25.01% | 22.95% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $32.38B | 14.51% | 21.84% | 21.53% | 32.27% |
| Zoetis Inc. (ZTS)vs › | $32.15B | 83.10% | 66.19% | 56.82% | 52.60% |
| Biogen Inc. (BIIB)vs › | $32.10B | 4.43% | 8.42% | 11.86% | 16.52% |
| Centene Corp. (CNC)vs › | $31.95B | -22.60% | -10.46% | -1.37% | 1.10% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $31.37B | 59.67% | -187.43% | 134.89% | 51.69% |
| Waters Corporation (WAT)vs › | $31.00B | 1.09% | 29.98% | 64.02% | 111.55% |
| Medline Inc. (MDLN)vs › | $29.72B | 5.97% | 9.02% | 4.86% | 4.86% |
ROE
3.0%
ROA
2.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 2.96% |
| 2026-03-31 | 3.66% |
| 2025-12-31 | 4.45% |
| 2025-09-30 | 4.75% |
| 2025-06-30 | 4.85% |
| 2025-03-31 | 5.09% |
| 2024-12-31 | 4.72% |
| 2024-09-30 | 5.43% |
| 2024-06-30 | 5.26% |
| 2024-03-31 | 5.03% |
| 2023-12-31 | 4.72% |
| 2023-09-30 | 2.23% |
| 2023-06-30 | 1.82% |
| 2023-03-31 | 1.72% |
| 2022-12-31 | 1.70% |
| 2022-09-30 | 2.91% |
| 2022-06-30 | 2.34% |
| 2022-03-31 | 2.36% |
| 2021-12-31 | 1.95% |
| 2021-09-30 | 1.74% |
| 2021-06-30 | 0.96% |
| 2021-03-31 | -2.06% |
| 2020-12-31 | -2.82% |
| 2020-09-30 | -3.84% |
| 2020-06-30 | -3.39% |
| 2020-03-31 | -3.15% |
| 2019-12-31 | -3.40% |
| 2019-09-30 | -3.29% |
| 2019-06-30 | -4.00% |
| 2019-03-31 | -1.65% |
| 2018-12-31 | -1.05% |
| 2018-09-30 | 0.73% |
